image credit: Adobe Stock

Ginkgo Bioworks Expands R&D Facilities with Opening of Bioworks7

January 9, 2023

Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has opened Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo increases its capacity and capabilities to serve its partners in the spaces of cell and gene therapy, biomanufacturing and general mammalian programming for therapeutic applications and new biopharmaceutical modalities.

Ginkgo’s foundry automates and scales the process of organism engineering, allowing engineers to prototype thousands of biological designs. This evolving platform equips companies and labs from startups to large pharmaceutical companies with access to robust technology, without the need to invest in costly lab and R&D infrastructure in-house and aims to drive down the cost per design.

Read More on Contract Pharma